SEC Form 4 · accession 0001209191-18-041240

ALDER BIOPHARMACEUTICALS INC · ALDR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Managing Director

Period of report

Jul 2, 2018

Accepted (ET)

Jul 3, 2018 · 5:28 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001423824

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Jul 2, 2018	M	7,121	$1.65	A	7,952	D
Common Stock^F1	Jul 2, 2018	M	5,040	$0.99	A	12,992	D
Common Stock^F2,F3	Jul 2, 2018	S	12,161	$15.4892	D	831	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$1.65	Jul 2, 2018	M	7,121	D	—	Jul 22, 2018	Common Stock	7,121	0	D
Stock Option (Right to Buy)^F4	$0.99	Jul 2, 2018	M	5,040	D	—	Apr 20, 2019	Common Stock	5,040	25,204	D

F1The stock option exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.225 to $15.775, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
F4The shares subject to this stock option are fully vested.